Professor, Obstetrics and Gynecology, UA College of Medicine-Phoenix
Obstetrics & Gynecology
Dr. Bradley J. Monk, MD
|
|
Give Review
Doctor Bradley J. Monk, MD practices Obstetrics & Gynecology. He went to medical school at University of Arizona College of Medicine - Tucson. University of Arizona College of Medicine - Tucson is ranked 67/42 in Research/PrimaryCare. He received 4 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Fellow (FACOG)" and "Fellow (FACS)". Bradley Monk is also a published MD. He has 100 publication published. The most recent publication is: Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. He accepts Medicare.
Publications
- Reply to F.M. Muggia.
- Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
- Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
- Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study.
- A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
- Reply to w.a.a. Tjalma and j.s. Grossman.
- In Assessing Surrogate Clinical Trial End Points: Drug Safety Is a Requisite.
- Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
- Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analys...
- Psychosocial Telephone Counseling for Survivors of Cervical Cancer: Results of a Randomized Biobehavioral Trial.
- Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: Characteristics associated with toxicity and the effect of substitution with...
- In vitro chemoresponse in metachronous pairs of ovarian cancers.
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Cervical Adenocarcinoma.
- Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer.
- New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.
- Factors Associated With Grade 3 or 4 Treatment-Related Toxicity in Women With Advanced or Recurrent Cervical Cancer: An Exploratory Analysis of NRG Oncology/Gynecologi...
- SGO guidance document for clinical trial designs in ovarian cancer: A changing paradigm.
- A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of t...
- Evidence-based therapy for recurrent cervical cancer.
- Factors associated with poor quality of life among cervical cancer survivors: Implications for clinical care and clinical trials.
- Bevacizumab in Treatment of High-Risk Ovarian Cancer--A Cost-Effectiveness Analysis.
- Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study.
- Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group.
- Improved survival with bevacizumab in advanced cervical cancer.
- A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
- Phase III Randomized Trial of Weekly Cisplatin and Irradiation Versus Cisplatin and Tirapazamine and Irradiation in Stages IB2, IIA, IIB, IIIB, and IVA Cervical Carcin...
- Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment.
- Impact of facility volume on therapy and survival for locally advanced cervical cancer.
- Ovarian Cancer Clinical Trial Endpoints: Society of Gynecologic Oncology White Paper.
- Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.
- Incidence and management of edema associated with trebananib (AMG 386).
- Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
- Latest research and treatment of advanced-stage epithelial ovarian cancer.
- Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: A Gynecologic Oncology Group study.
- Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
- Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent...
- Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer.
- Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer.
- Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiati...
- Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecolo...
- Survival Data From a Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy in Patients With Advanced and Recurrent Cervical Cancer.
- An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
- A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study.
- American society of clinical oncology 2011 annual meeting update: summary of selected gynecologic cancer abstracts.
- Differentiating squamous cell carcinoma of the cervix and epithelioid trophoblastic tumor.
- Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.
- Comments on: "Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens" (Monk BJ, Si...
- Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
- A randomized phase III trial of IV carboplatin and paclitaxel à 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-...
- Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial.
- Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gy...
- An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in...
- Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gyn...
- Biologics in cervical cancer therapy.
- Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study.
- Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
- High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays.
- American Society of Clinical Oncology 2010 Annual Meeting update: summary of selected gynecologic cancer abstracts.
- Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cer...
- Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
- Bevacizumab toxicities and their management in ovarian cancer.
- A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study.
- Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.
- The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecolo...
- Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
- The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.
- Anti-angiogenesis agents in metastatic or recurrent cervical cancer.
- Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.
- Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic onco...
- Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compo...
- Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.
- Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
- Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience.
- Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to pr...
- When is being in a hurry going too fast? Lessons learned from clinical trials in cervical cancer.
- Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
- What is the standard therapy for bulky stage IB cervical cancer?
- Green tea catechins for treatment of external genital warts.
- Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
- Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
- A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
- A clinical pathway for postoperative management and early patient discharge: does it work in gynecologic oncology?
- The pediatrician's role in preventing cervical cancer.
- Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease.
- Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease.
- The impact of cervical cancer on quality of life: a personal account.
- The new era of cervical cancer prevention: HPV vaccination.
- Age considerations when vaccinating against HPV.
- Initial lessons learned in HPV vaccination.
- Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected].
- Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?
- The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative.
- Reducing the burden of glandular carcinomas of the uterine cervix.
- Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
- The spectrum and clinical sequelae of human papillomavirus infection.
- The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination.
- Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
- An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy.
- Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions.
Schools
University Of Arizona College Of Medicine
University Of California Los Angeles
University Of Calif Irvine Med Cent
Procedures Preformed
- Abdominal Hysterectomy With Robotic Assistance
- Colpopexy
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Fellow (FACOG)
- Fellow (FACS)
Education
-
University of California Irvine -
UCLA Medical Center -
University of Arizona College of Medicine - Tucson
Hospital
-
Chandler Regional Medical Center -
Mercy Gilbert Medical Center -
St. Joseph's Hospital and Medical Center
Drug Facts
| NPI NUMBER | 1487734646 | |
| NPPES Provider LastName | MONK | |
| NPPES Provider FirstName | BRADLEY | |
| NPPES Provider ZIPCode | 850134224 | |
| NPPES Provider State | AZ | |
| Specialty Description | Obstetrics/Gynecology | |
| Total Claim Count | 26.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487734646 |
| Last Name Of The Provider | MONK |
| First Name Of The Provider | BRADLEY |
| View All |
Similar Doctors
|
Dr. Dana M. Chase, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Javier F. Magrina, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Lyndsay J. Willmott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert S. Rigberg, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Corey S. Bruce, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. M L. Holemon, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tracy Contant, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Galen B. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul M. Magtibay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bojan L. Malmin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Travis J. Powell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nichelle E. Whitehead, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Edward J. Rotmensch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alan N. Gordon, MD
This Doctor is OpenDoctor Recommended.
|